TY - JOUR
T1 - Magnetic resonance imaging in multiple sclerosis animal models
T2 - A systematic review, meta-analysis, and white paper
AU - Ineichen, Benjamin V.
AU - Sati, Pascal
AU - Granberg, Tobias
AU - Absinta, Martina
AU - Lee, Nathanael J.
AU - Lefeuvre, Jennifer A.
AU - Reich, Daniel S.
N1 - Publisher Copyright:
© 2020 The Authors
PY - 2020
Y1 - 2020
N2 - Magnetic resonance imaging (MRI) is the most important paraclinical tool for assessing drug response in multiple sclerosis (MS) clinical trials. As such, MRI has also been widely used in preclinical research to investigate drug efficacy and pathogenic aspects in MS animal models. Keeping track of all published preclinical imaging studies, and possible new therapeutic approaches, has become difficult considering the abundance of studies. Moreover, comparisons between studies are hampered by methodological differences, especially since small differences in an MRI protocol can lead to large differences in tissue contrast. We therefore provide a comprehensive qualitative overview of preclinical MRI studies in the field of neuroinflammatory and demyelinating diseases, aiming to summarize experimental setup, MRI methodology, and risk of bias. We also provide estimates of the effects of tested therapeutic interventions by a meta-analysis. Finally, to improve the standardization of preclinical experiments, we propose guidelines on technical aspects of MRI and reporting that can serve as a framework for future preclinical studies using MRI in MS animal models. By implementing these guidelines, clinical translation of findings will be facilitated, and could possibly reduce experimental animal numbers.
AB - Magnetic resonance imaging (MRI) is the most important paraclinical tool for assessing drug response in multiple sclerosis (MS) clinical trials. As such, MRI has also been widely used in preclinical research to investigate drug efficacy and pathogenic aspects in MS animal models. Keeping track of all published preclinical imaging studies, and possible new therapeutic approaches, has become difficult considering the abundance of studies. Moreover, comparisons between studies are hampered by methodological differences, especially since small differences in an MRI protocol can lead to large differences in tissue contrast. We therefore provide a comprehensive qualitative overview of preclinical MRI studies in the field of neuroinflammatory and demyelinating diseases, aiming to summarize experimental setup, MRI methodology, and risk of bias. We also provide estimates of the effects of tested therapeutic interventions by a meta-analysis. Finally, to improve the standardization of preclinical experiments, we propose guidelines on technical aspects of MRI and reporting that can serve as a framework for future preclinical studies using MRI in MS animal models. By implementing these guidelines, clinical translation of findings will be facilitated, and could possibly reduce experimental animal numbers.
KW - Animal models
KW - Guidelines
KW - Magnetic resonance imaging (MRI)
KW - Meta-analysis
KW - Multiple sclerosis (MS)
KW - Systematic review
UR - http://www.scopus.com/inward/record.url?scp=85089431860&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089431860&partnerID=8YFLogxK
U2 - 10.1016/j.nicl.2020.102371
DO - 10.1016/j.nicl.2020.102371
M3 - Article
C2 - 32818883
AN - SCOPUS:85089431860
SN - 2213-1582
VL - 28
JO - NeuroImage: Clinical
JF - NeuroImage: Clinical
M1 - 102371
ER -